Education: MD, PhD
MRC Laboratory of Molecular Biology
Cambridge University, Cambridge, UK - 1992
Oxford University Medical School, Oxford, UK – 1995
Dr. Camidge joined the University of Colorado as a visiting professor in November of 2005, and was recruited as full-time faculty in October of 2007. He is dual-trained in both medical oncology and clinical pharmacology.
Dr Camidge is the Director of the Thoracic Oncology Clinical and Clinical Research Programs at the University of Colorado. His focus is in Thoracic Malignancies and Developmental Therapeutics (Phase I studies). In 2012, he was announced as the recipient of the 5th Bonnie J. Addario Lectureship as a ‘Luminary in the quest to eradicate lung cancer.’ In 2013, he became the first physician to receive the Hank Baskett Sr. Spirit Award, for which he was credited as being ‘one of the leading minds in lung cancer today.’ In 2015, he became the inaugural holder of the Joyce Zeff Chair in Lung Cancer Research at the University of Colorado Cancer Center and in 2016, the Lung
Cancer Foundation presented him with the Breath Away From The Cure Award being
described as ‘Simply one of the best in treating lung cancer today.’
Dr Camidge is also
the National Medical Director of the Academic Thoracic Oncology Medical
Investigators Consortium (ATOMIC) and a member of the National Comprehensive
Cancer Network Lung Cancer Committee.
Dr Camidge has been
principal investigator on numerous clinical trials in early phase drug
development and thoracic malignancies. He has authored more than 150 articles
and reviews in peer-reviewed journals such as Cancer, Journal of Clinical
Oncology, Journal of Thoracic Oncology and The New England Journal of Medicine.
He has presented his research at multiple national and international scientific
In addition to training Fellows through the CU ACGME Medical Oncology Fellowship, Dr Camidge is also the Director of the CU Senior Thoracic Oncology Clinical and Translational Research Fellowship - a unique ‘finishing school’ in advanced cancer clinical research for US and International Graduates who have already completed their basic Medical Oncology training. Through these two programs, Dr Camidge has mentored a consistent series of outstanding early career medical oncologists. In 2014, he was nationally recognized by The Quality of Life Center at Claremont University in California as an ‘Exemplary mentor in the positive development of junior colleagues in the profession.’
The intersecting Developmental Therapeutics and Thoracic Oncology Programs at CU acquire access to a broad range of new drugs offering outstanding opportunities for developing new therapies for patients with thoracic malignancies. Dr Camidge has been principal investigator on numerous clinical trials in early phase drug development and thoracic malignancies. He has authored more than 100 articles in peer-reviewed journals such as Cancer, Journal of Clinical Oncology, Journal of Thoracic Oncology, and The New England Journal of Medicine as well as several book chapters. He has presented his research at multiple national and international scientific symposia.
- IASLC Young investigator Award and University of Colorado Lung Cancer SPORE Pilot Project Award: Mechanisms of cell death in non-small-cell lung cancer.
- NIH R21: Phase I dose-escalation/randomized Phase II cross-over study of anti-IGF-1R monoclonocal antibody IMC-A12 in patients with advanced non-small cell lung cancer.
- Bonnie J. Addario Lung Cancer Foundation: Comparison of ALK detection methodologies; Detecting RET gene rearrangements in NSCLC.
- South West Oncology Group: SWOG1300 - A randomized, phase II trial of crizotinib plus pemetrexed versus pemetrexed alone in ALK-positive non-squamous NSCLC patients who have progressed systemically after previous clinical benefit from crizotinib monotherapy.
In addition, Dr. Camidge has written and is/has been the Principal Investigator on a number of Investigator Initiated Clinical Trials in the Thoracic Malignancies and Developmental Therapeutics programs, either taken on and run by the pharmaceutical industry directly including from Boehringer Ingeleheim (High Dose Intermittent (HDI) afatinib), or run through UCCC funded by industry-related grants including from Bayer/Onyx and Merck (sorafenib in combination with vorinostat); and Ariad (ponatinib).
Sequist LV, Soria JC, Goldman JW, Wakelee HA, Gadgeel SM, Varga A, Papadimitrakopoulou V, Solomon BJ, Oxnard GR, Dziadziuszko R, Aisner DL, Doebele RC, Galasso C, Garon EB, Heist RS, Logan J, Neal JW, Mendenhall MA, Nichols S, Piotrowska Z, Wozniak AJ, Raponi M, Karlovich CA, Jaw-Tsai S, Isaacson J, Despain D, Matheny SL, Rolfe L, Allen AR, Camidge DR. Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer. New England Journal of Medicine 2015 Apr 30;372(18):1700-1709.
Shaw AT, Ou S-H I, Bang Y-J, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve M, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-Rearranged Non-Small Cell Lung Cancer. New England Journal of Medicine 2014 Nov 20;371(21):1963-71
Camidge DR, Brosnan EM, DeSilva C, Koo PJ, Chonchol M. Crizotinib effects on creatinine and non-creatinine-based measures of glomerular filtration rate. J Thoracic Oncology 2014 9(11):1634-7.
Camidge DR, Berge EM, Doebele RC, Ballas MS, Jahan T, Haigentz M Jr, Hoffman D, Spicer J, West H, Lee P, Yang L, Joshi A, Gao L, Yurasov S, Mita A. A Phase II, Open-Label Study of Ramucirumab in Combination with Paclitaxel and Carboplatin as First-Line Therapy in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014 Aug 28
Browning ET, Huckleberry JM, Barrow WB, Restauri NL, Kemme DJ, Cool CD, Weyant MJ, Franklin WA, Camidge DR. Downstaging of Non-Small-Cell Lung Cancer Through Identification of Reversible Drug Toxicity. J Clin Oncol. 2014 May 5. [Epub ahead of print]
Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, Camidge DR, Vansteenkiste J, Sharma S, De Pas T, Riely GJ, Solomon BJ, Wolf J, Thomas M, Schuler M, Liu G, Santoro A, Lau YY, Goldwasser M, Boral AL, Engelman JA. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Mar 27;370(13):1189-97.
von Pawel J, Harvey JH, Spigel DR, Dediu M, Reck M, Cebotaru CL, Humphreys RC, Gribbin MJ, Fox NL, Camidge DR. Phase II Trial of Mapatumumab, a Fully Human Agonist Monoclonal Antibody to Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptor 1 (TRAIL-R1), in Combination With Paclitaxel and Carboplatin in Patients With Advanced Non-Small-Cell Lung Cancer. Clinical Lung Cancer. 2013 Dec 27. pii: S1525-7304(13)00262-3. [Epub ahead of print]
Ren S, Hirsch FR, Varella-Garcia M, Aisner DL, Boyle T, Zhou C, Camidge DR. Atypical Negative ALK Break-Apart FISH Harboring a Crizotinib-Responsive ALK Rearrangement in Non-Small-Cell Lung Cancer. J Thorac Oncol. 2014 Mar;9(3):e21-3.
Gan GN, Weickhardt AJ, Scheier B, Doebele RC, Gaspar LE, Kavanagh BD, Camidge DR. Stereotactic Radiation Therapy can Safely and Durably Control Sites of Extra-Central Nervous System Oligoprogressive Disease in Anaplastic Lymphoma Kinase-Positive Lung Cancer Patients Receiving Crizotinib. Int J Radiat Oncol Biol Phys. 2014 Mar 15;88(4):892-8.
Brosnan EM, Weickhardt AJ, Lu X, Maxon DA, Barón AE, Chonchol M, Camidge DR. Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer. 2013 Nov 20. doi: 10.1002/cncr.28478. [Epub ahead of print]
Camidge DR, Skokan M, Kiatsimkul P, Helfrich B, Lu X, Barón AE, Schulte N, Maxson D, Aisner DL, Franklin WA, Doebele RC, Varella-Garcia M. Native and rearranged ALK copy number and rearranged cell count in non-small cell lung cancer: Implications for ALK inhibitor therapy. Cancer. 2013 Nov 15;119(22):3968-75.
Berge EM, Lu X, Maxson D, Barón AE, Gadgeel SM, Solomon BJ, Doebele RC, Varella-Garcia M, Camidge DR. Clinical Benefit From Pemetrexed Before and After Crizotinib Exposure and From Crizotinib Before and After Pemetrexed Exposure in Patients With Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer. Clinical Lung Cancer 2013 Aug 6. [Epub ahead of print]
Shaw AT, Kim D-W, Nakagawa K, Seto T, Crinó L, Ahn M-J, de Pas T, Besse B, Solomon BJ, Blackhall F, Wu Y-L, Thomas M, O’Byrne KJ, Moro-Sibilot D, Camidge DR, Mok T, Hirsh V, Riely GJ, Iyer S, Tassell V, Polli A, Wilner KD, Jänne PA. Crizotinib versus Chemotherapy in Advanced ALK-rearranged Lung Cancer. New England Journal of Medicine 2013 368(25):2385-94
Diamond JR, Salgia R, Varella-Garcia M, Kanteti R, Lorusso PM, Clark JW, Xu LG, Wilner K, Eckhardt SG, Ching KA, Lira ME, Schoenmakers EF, Christensen JG, Camidge DR. Initial Clinical Sensitivity and Acquired Resistance to MET Inhibition in MET-Mutated Papillary Renal Cell Carcinoma. Journal of Clinical Oncology 2013 Apr 22. [Epub ahead of print]
Weickhardt AJ, Doebele RC, Purcell WT, Bunn PA, Oton AB, Rothman MS, Wierman ME, Mok T, Popat S, Bauman J, Nieva J, Novello S, Ou S-HI, Camidge DR. Symptomatic reduction in free testosterone levels secondary to crizotinib use in male cancer patients. Cancer 2013 Jul 1;119(13):2383-90.
Browning ET, Weickhardt AJ, Camidge DR. Response to Crizotinib Rechallenge after Initial Progression and Intervening Chemotherapy in ALK Lung Cancer. Journal of Thoracic Oncology 2013 Mar;8(3):e21. [Epub ahead of print]
Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn PA Jr, Aisner DL, Gaspar LE, Kavanagh BD, Doebele RC, Camidge DR. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. Journal of Thoracic Oncology 2012 Dec;7(12):1807-14.
Camidge DR, Blais N, Jonker DJ, Soulières D, Doebele RC, Ruiz-Garcia A, Thall A, Zhang K, Laurie SA, Chao RC, Chow LQ. Sunitinib combined with pemetrexed and cisplatin: results of a phase I dose-escalation and pharmacokinetic study in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer and mesothelioma. Cancer Chemotherapy and Pharmacology 2012 Oct 30. [Epub ahead of print]
Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, Riely GJ, Solomon B, Ou SH, Kim DW, Salgia R, Fidias P, Engelman JA, Gandhi L, Jänne PA, Costa DB, Shapiro GI, Lorusso P, Ruffner K, Stephenson P, Tang Y, Wilner K, Clark JW, Shaw AT. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol. 2012 13(10):1011-9.
Weickhardt AJ, Rothman MS, Salian-Mehta S, Kiseljak-Vassiliades K, Oton AB, Doebele RC, Wierman ME, Camidge DR. Rapid-onset hypogonadism secondary to crizotinib use in men with metastatic nonsmall cell lung cancer. Cancer 2012 Apr 4. doi: 10.1002/cncr.27450. [Epub ahead of print]
Dasari A, Gore L, Messersmith WA, Diab S, Jimeno A, Weekes CD, Lewis KD, Drabkin HA, Flaig TW, Camidge DR. A phase I study of sorafenib and vorinostat in patients with advanced solid tumors with expanded cohorts in renal cell carcinoma and non-small cell lung cancer. Investigational New Drugs 2012 Mar 14. [Epub ahead of print]
Atherly AJ, Camidge DR. The cost-effectiveness of screening lung cancer patients for targeted drug sensitivity markers. British Journal of Cancer 2012 Feb 28. doi: 10.1038/bjc.2012.60. [Epub ahead of print]
Doebele RC, Conkling P, Traynor AM, Otterson GA, Zhao Y, Wind S, Stopfer P, Kaiser R, Camidge DR. A phase I, open-label, dose-escalation study of continuous treatment with BIBF 1120 in combination with paclitaxel and carboplatin in patients with advanced non-small cell lung cancer. Annals of Oncology 2012; doi: 10.1093/annonc/mdr596
West HJ, Camidge DR. Have mutation, will travel: utilizing online patient communities and new trial strategies to optimize clinical research in the era of molecularly diverse oncology. J Thorac Oncol. 2012 Mar;7(3):482-4.
Camidge DR, Theodoro M, Maxson DA, Skokan M, O'Brien T, Lu X, Doebele RC, Barón AE, Varella-Garcia M. Correlations between the percentage of tumor cells showing an ALK (anaplastic lymphoma kinase) gene rearrangement, ALK signal copy number, and response to crizotinib therapy in ALK fluorescence in situ hybridization-positive nonsmall cell lung cancer. Cancer. 2012 Jan 26. doi: 10.1002/cncr.27411. [Epub ahead of print]
Doebele RC, Lu X, Sumey C, Maxson DA, Weickhardt AJ, Oton AB, Bunn PA Jr, Barón AE, Franklin WA, Aisner DL, Varella-Garcia M, Camidge DR. Oncogene status predicts patterns of metastatic spread in treatment-naive nonsmall cell lung cancer. Cancer. 2012 Jan 26. doi: 10.1002/cncr.27409. [Epub ahead of print]
Weickhardt A, Doebele R, Oton A, Lettieri J, Maxson D, Reynolds M, Brown A, Jackson MK, Dy G, Adjei A, Fetterly G, Lu X, Franklin W, Varella-Garcia M, Hirsch FR, Wynes MW, Youssoufian H, Adjei A, Camidge DR. A Phase I/II Study of Erlotinib in Combination with the Anti-Insulin-Like Growth Factor-1 Receptor Monoclonal Antibody IMC-A12 (Cixutumumab) in Patients with Advanced Non-small Cell Lung Cancer. Journal of Thoracic Oncology 2012 Jan 10. [Epub ahead of print]
Doebele RC, Pilling AB, Aisner D, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA, Varella-Garcia M, Camidge DR. Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non-Small Cell Lung Cancer. Clinical Cancer Research 2012 Jan 10. [Epub ahead of print]
Chow LQ, Blais N, Jonker DJ, Laurie SA, Diab SG, Canil C, McWilliam M, Thall A, Ruiz-Garcia A, Zhang K, Tye L, Chao RC, Camidge DR. A phase I dose-escalation and pharmacokinetic study of sunitinib in combination with pemetrexed in patients with advanced solid malignancies, with an expanded cohort in non-small cell lung cancer. Cancer Chemother Pharmacol. 2011 Oct 12. [Epub ahead of print]
Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, Shapiro GI, Costa DB, Ou SH, Butaney M, Salgia R, Maki RG, Varella-Garcia M, Doebele RC, Bang YJ, Kulig K, Selaru P, Tang Y, Wilner KD, Kwak EL, Clark JW, Iafrate AJ, Camidge DR. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncology 2011 Sep 16. [Epub ahead of print]
Hirsch FR, Kabbinavar F, Eisen T, Martins R, Schnell FM, Dziadziuszko R, Richardson K, Richardson F, Wacker B, Sternberg DW, Rusk J, Franklin WA, Varella-Garcia M, Bunn PA Jr, Camidge DR. A Randomized, Phase II, Biomarker-Selected Study Comparing Erlotinib to Erlotinib Intercalated With Chemotherapy in First-Line Therapy for Advanced Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2011; 29(26):3567-35 73.
Camidge DR, Kono SA, Lu X, Okuyama S, Baron AE, Oton AB, Davies AM, Varella-Garcia M, Franklin WA, Doebele RC. Anaplastic Lymphoma Kinase (ALK) gene rearrangements in non-small cell lung cancer are associated with prolonged progression free survival on pemetrexed. Journal of Thoracic Oncology 2011; 6(4):774-780
Camidge DR, Kono SA, Flacco A, Tan A-C, Doebele RC, Zhou Q, Crino L, Franklin WA, Varella-Garcia M. Optimizing the detection of lung cancer patients harboring Anaplastic Lymphoma Kinase (ALK) gene rearrangements potentially suitable for ALK inhibitor treatment. Clinical Cancer Research 2010; 16(22):5581-5590
Kwak L, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB, Varella-Garcia M, Kim WH, Lynch TJ, Fidias P, Stubbs H, Engelman JA, Sequist LV, Tan W, Gandhi L, Mino-Kenudson M, Wei GC, Shreeve SM, Ratain MJ, Settleman J, Christensen JG, Haber DA, Wilner K, Salgia R, Shapiro GI, Clark JW, Iafrate AJ. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. New England Journal of Medicine 2010; 363:1693-1703
Narayanan V, Honce MJ, Mehrotra S, Camidge DR. Cystic Brain Metastases
Occurring in Anaplastic Lymphoma Kinase Gene Rearranged Non-Small-Cell Lung
Cancer Patients Receiving Crizotinib. Clin Lung Cancer. 2015 Jul 30. pii:
Noonan SA, Camidge
DR. PROFILE 1014: lessons for the new era of lung cancer clinical research.
Transl Lung Cancer Res. 2015 Oct;4(5):642-8.
Womack JP, Varella-Garcia M, Camidge DR. Waxing and Waning of MET Amplification in EGFR-Mutated
NSCLC in Response to the Presence and Absence of Erlotinib Selection Pressure.
J Thorac Oncol. 2015 Dec;10(12):e115-8.
McCoach CE, Berge EM, Lu X, Barón AE, Camidge DR. A Brief Report of the
Status of Central Nervous System Metastasis Enrollment Criteria for Advanced
Non-Small Cell Lung Cancer Clinical Trials: A Review of the ClinicalTrials.gov
Trial Registry. J Thorac Oncol. 2015 Dec 24. pii: S1556-0864(15)00047-7.
Youngwerth JM, Camidge
DR. Palliative Care as a Partner, Not an Alternative, to Active Anicancer
Care: Will the United States Catch Up With the Rest of the World? (Opinion
Piece) Current Insights in Oncology, ASCO
Connection 2016; May: 27-29.
Noonan SA, Berry L, Lu X, Gao D, Barón AE, Chesnut
P, Sheren J, Aisner DL, Merrick D, Doebele RC, Varella-Garcia M, Camidge DR. Identifying the appropriate
FISH criteria for defining MET copy number driven lung adenocarcinoma through
oncogene overlap analysis. J Thorac Oncol.
2016 Jun 1.
Aisner DL, Rumery MD, Merrick DT, Kondo KL, Nijmeh
H, Linderman DJ, Doebele RC, Thomas N, Chesnut PC, Varella-Garcia M, Franklin
WA, Camidge DR. Do More With Less:
Tips and Techniques for Maximizing Small Biopsy and Cytology Specimens for
Molecular and Ancillary Testing: The University of Colorado Experience. Arch Pathol Lab Med. 2016 Sep 9.
Noonan SA, Sachs PB, Camidge DR. Brief report:Transient asymptomatic pulmonary opacities
occurring during osimertinib treatment. J
Thorac Oncol. 2016 Sep 9. pii: S1556-0864(16)30929-7.
Camidge DR. Watching nivolumab’s balancing act: How immune
activation may affect both safety and efficacy in patients with advanced
melanoma. (Editorial Podcast). Journal of
Clinical Oncology 2016; September 19th.
Gettinger SN, Bazhenova LA, Langer CJ, Salgia R,
Gold KA, Rosell R, Shaw AT, Weiss GJ, Tugnait M, Narasimhan NI, Dorer DJ,
Kerstein D, Rivera VM, Clackson T, Haluska FG, Camidge DR. Activity and safety of brigatinib in ALK-rearranged
non-small-cell lung cancer and other malignancies: a single-arm, open-label,
phase 1/2 trial. Lancet Oncol. 2016